454 related articles for article (PubMed ID: 17444854)
1. Predictors of alpha-fetoprotein elevation in patients with chronic hepatitis C, but not hepatocellular carcinoma, and its normalization after pegylated interferon alfa 2a-ribavirin combination therapy.
Chen TM; Huang PT; Tsai MH; Lin LF; Liu CC; Ho KS; Siauw CP; Chao PL; Tung JN
J Gastroenterol Hepatol; 2007 May; 22(5):669-75. PubMed ID: 17444854
[TBL] [Abstract][Full Text] [Related]
2. Assessment of hepatocellular carcinoma risk based on peg-interferon plus ribavirin treatment experience in this new era of highly effective oral antiviral drugs.
Lee SH; Jin YJ; Shin JY; Lee JW
Medicine (Baltimore); 2017 Jan; 96(1):e5321. PubMed ID: 28072684
[TBL] [Abstract][Full Text] [Related]
3. Immunogenicity of recombinant hepatitis B vaccine in treatment-naive and treatment-experienced chronic hepatitis C patients: the effect of pegylated interferon plus ribavirin treatment.
Elefsiniotis IS; Vezali E; Kamposioras K; Pantazis KD; Tontorova R; Ketikoglou I; Moulakakis A; Saroglou G
World J Gastroenterol; 2006 Jul; 12(27):4420-4. PubMed ID: 16865790
[TBL] [Abstract][Full Text] [Related]
4. Diabetic patients with chronic hepatitis C virus response compared to non diabetics when treated with directly acting antiviral therapy.
Marzaban RN; AlMekhzangy HI; ElAkel W; ElBaz TM; ElShazly YM; ElSaeed K; Anees M; Said M; ElSerafy MA; Esmat GG; Doss WH
Arab J Gastroenterol; 2024 May; 25(2):118-124. PubMed ID: 38378359
[TBL] [Abstract][Full Text] [Related]
5. Lysyl oxidase-like 2 as a predictor of hepatocellular carcinoma in patients with hepatitis C virus after sustained virological response.
Chida T; Ohta K; Noritake H; Matsushita M; Murohisa G; Kageyama F; Sasada Y; Oyaizu T; Tsugiki M; Tamakoshi K; Nakajima T; Suda T; Kawata K
Sci Rep; 2024 May; 14(1):10864. PubMed ID: 38740815
[TBL] [Abstract][Full Text] [Related]
6. IMPACT OF THE PEGYLATED-INTERFERON AND RIBAVIRIN THERAPY ON THE TREATMENT-RELATED MORTALITY OF PATIENTS WITH CIRRHOSIS DUE TO HEPATITIS C VIRUS.
Dresch KF; Mattos AA; Tovo CV; Onofrio FQ; Casagrande L; Feltrin AA; Barros IC; Almeida PR
Rev Inst Med Trop Sao Paulo; 2016; 58():37. PubMed ID: 27253739
[TBL] [Abstract][Full Text] [Related]
7. Dynamic interplay between CXCL levels in chronic hepatitis C patients treated by interferon.
Zekri AR; Bahnassy AA; Mohamed WS; Alam El-Din HM; Shousha HI; Zayed N; Eldahshan DH; Abdel-Aziz AO
Virol J; 2013 Jul; 10():218. PubMed ID: 23816271
[TBL] [Abstract][Full Text] [Related]
8. Detection of hepatocellular carcinoma at advanced stages among patients in the HALT-C trial: where did surveillance fail?
Singal AG; Nehra M; Adams-Huet B; Yopp AC; Tiro JA; Marrero JA; Lok AS; Lee WM
Am J Gastroenterol; 2013 Mar; 108(3):425-32. PubMed ID: 23337478
[TBL] [Abstract][Full Text] [Related]
9. Efficacy of interferon dose and prediction of response in chronic hepatitis C: Benelux study in 336 patients.
Brouwer JT; Nevens F; Kleter B; Elewaut A; Adler M; Brenard R; Chamuleau RA; Michielsen PP; Pirotte J; Hautekeete ML; Weber J; Bourgeois N; Hansen BE; Bronkhorst CM; ten Kate FJ; Heijtink RA; Fevery J; Schalm SW
J Hepatol; 1998 Jun; 28(6):951-9. PubMed ID: 9672169
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and tolerance of a 6-month treatment course of daily interferon-alpha 2a for chronic hepatitis C with cirrhosis. The Australian Hepatitis C Study Group.
Farrell G; Cooksley WG; Dudley FJ; Watson K
J Viral Hepat; 1997 Sep; 4(5):317-23. PubMed ID: 9310930
[TBL] [Abstract][Full Text] [Related]
11. Low levels of microbial translocation marker LBP are associated with sustained viral response after anti-HCV treatment in HIV-1/HCV co-infected patients.
Nyström J; Stenkvist J; Häggblom A; Weiland O; Nowak P
PLoS One; 2015; 10(3):e0118643. PubMed ID: 25785448
[TBL] [Abstract][Full Text] [Related]
12. Changes of shear-wave velocity by interferon-based therapy in chronic hepatitis C.
Osakabe K; Ichino N; Nishikawa T; Sugiyama H; Kato M; Shibata A; Asada W; Kawabe N; Hashimoto S; Murao M; Nakano T; Shimazaki H; Kan T; Nakaoka K; Takagawa Y; Ohki M; Kurashita T; Takamura T; Yoshioka K
World J Gastroenterol; 2015 Sep; 21(35):10215-23. PubMed ID: 26401087
[TBL] [Abstract][Full Text] [Related]
13. Estimation of direct medical cost related to the management of chronic hepatitis C and its complications in South Korea.
Kim DY; Yoon KT; Kim W; Lee JI; Hong SH; Lee D; Jang JW; Choi JW; Kim I; Paik YH
Medicine (Baltimore); 2016 Jul; 95(30):e3896. PubMed ID: 27472670
[TBL] [Abstract][Full Text] [Related]
14. Development of models estimating the risk of hepatocellular carcinoma after antiviral treatment for hepatitis C.
Ioannou GN; Green PK; Beste LA; Mun EJ; Kerr KF; Berry K
J Hepatol; 2018 Nov; 69(5):1088-1098. PubMed ID: 30138686
[TBL] [Abstract][Full Text] [Related]
15. Relation of interferon therapy and hepatocellular carcinoma in patients with chronic hepatitis C. Osaka Hepatocellular Carcinoma Prevention Study Group.
Imai Y; Kawata S; Tamura S; Yabuuchi I; Noda S; Inada M; Maeda Y; Shirai Y; Fukuzaki T; Kaji I; Ishikawa H; Matsuda Y; Nishikawa M; Seki K; Matsuzawa Y
Ann Intern Med; 1998 Jul; 129(2):94-9. PubMed ID: 9669992
[TBL] [Abstract][Full Text] [Related]
16. Analyzing risk factors and developing a stratification system for hepatocellular carcinoma recurrence after interferon-free direct-acting antiviral therapy in chronic hepatitis C patients.
Luan CH; Su PS; Chu CJ; Lin CC; Su CW; Luo JC; Lee IC; Chi CT; Lee SD; Wang YJ; Lee FY; Huang YH; Hou MC
J Chin Med Assoc; 2024 Apr; 87(4):357-368. PubMed ID: 38180018
[TBL] [Abstract][Full Text] [Related]
17. Randomised trial of effects of interferon-alpha on incidence of hepatocellular carcinoma in chronic active hepatitis C with cirrhosis.
Nishiguchi S; Kuroki T; Nakatani S; Morimoto H; Takeda T; Nakajima S; Shiomi S; Seki S; Kobayashi K; Otani S
Lancet; 1995 Oct; 346(8982):1051-5. PubMed ID: 7564784
[TBL] [Abstract][Full Text] [Related]
18. Serum fibrosis markers are associated with liver disease progression in non-responder patients with chronic hepatitis C.
Fontana RJ; Dienstag JL; Bonkovsky HL; Sterling RK; Naishadham D; Goodman ZD; Lok AS; Wright EC; Su GL;
Gut; 2010 Oct; 59(10):1401-9. PubMed ID: 20675691
[TBL] [Abstract][Full Text] [Related]
19. A pilot study of combination therapy with ribavirin plus interferon alfa for interferon alfa-resistant chronic hepatitis C.
Brillanti S; Garson J; Foli M; Whitby K; Deaville R; Masci C; Miglioli M; Barbara L
Gastroenterology; 1994 Sep; 107(3):812-7. PubMed ID: 7521308
[TBL] [Abstract][Full Text] [Related]
20. Baseline level and early suppression of serum HCV RNA for predicting sustained complete response to alpha-interferon therapy.
Izopet J; Payen JL; Alric L; Sandres K; Charlet JP; Vinel JP; Duffaut M; Pascal JP; Puel J
J Med Virol; 1998 Feb; 54(2):86-91. PubMed ID: 9496364
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
